IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
Portfolio Pulse from Benzinga Newsdesk
IGM Biosciences has received FDA clearance to begin Phase 1b clinical studies of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, for severe systemic lupus erythematosus (SLE) and severe rheumatoid arthritis (RA). Patient enrollment is expected to start in Q3 2023.
May 31, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IGM Biosciences' FDA clearance for imvotamab clinical studies in severe lupus and rheumatoid arthritis may positively impact the company's stock in the short term.
The FDA clearance for imvotamab clinical studies in severe lupus and rheumatoid arthritis is a significant milestone for IGM Biosciences. This news may increase investor confidence in the company's product pipeline and lead to a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100